X
[{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics to Present Interim Clinical Data for TriTAC\u00ae HPN424 at the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC\u2122 Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EPCAM ProTriTAC\u2122 Program at 35th SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Reports Clinical Progress Across All Four Tritac\u00ae Pipeline Development Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Provides Pipeline Update for TriTAC Clinical Programs and T Cell Engager Platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"New Leaf","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harpoon Therapeutics Announces Closing of $25 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Soleus Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harpoon Therapeutics Announces up to $150 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$680.0 million","upfrontCash":"$680.0 million","newsHeadline":"Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck Completes Acquisition of Harpoon Therapeutics, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Harpoon Therapeutics
Filters
Companies By Therapeutic Area
Details:
Through the acquisition, Merck leverages Harpoon lead candidate HPN328 (MK-6070), which is being evaluated in Phase I/II clinical trial studies in combination with Atezolizumab for the treatment of Small-cell Lung Cancer.
Lead Product(s):
MK-6070,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Merck & Co
Deal Size: $650.0 millionUpfront Cash: Undisclosed
Deal Type: AcquisitionMarch 11, 2024
Details:
The acquisition will expand Merck's oncology portfolio by including HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors.
Lead Product(s):
HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Merck & Co
Deal Size: $680.0 millionUpfront Cash: $680.0 million
Deal Type: AcquisitionJanuary 08, 2024
Details:
The Company intends to use the proceeds to fund its clinical development programs from its platforms, including ongoing as well as future late-stage clinical studies of HPN328, a TriTAC that binds to human and non-human primate DLL3, CD3ε, and albumin with similar affinities.
Lead Product(s):
HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Soleus Capital
Deal Size: $150.0 millionUpfront Cash: Undisclosed
Deal Type: Private PlacementOctober 23, 2023
Details:
HPN328, is a DLL3 targeting TriTAC®, which is investigated in combination with atezolizumab for the treatment of patients with small cell lung cancer.
Lead Product(s):
HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
F. Hoffmann-La Roche
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableSeptember 15, 2023
Details:
Under the agreement, AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA.
Lead Product(s):
HPN217
Therapeutic Area: Oncology Product Name: HPN217
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator:
AbbVie Inc
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: AgreementSeptember 13, 2023
Details:
HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells and investigated for Relapsed/Refractory Multiple Myeloma.
Lead Product(s):
HPN217
Therapeutic Area: Oncology Product Name: HPN217
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableJune 27, 2023
Details:
The proceeds will be used to complete ongoing Phase 1 clinical studies for TriTAC® T cell engagers, including HPN217 (BCMA) in Phase 1 for patients with relapsed and refractory multiple myeloma, and HPN328 (DLL3), in Phase 1/2 for patients with multiple neuroendocrine tumors.
Lead Product(s):
HPN217
Therapeutic Area: Oncology Product Name: HPN217
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator:
New Leaf
Deal Size: $25.0 millionUpfront Cash: Undisclosed
Deal Type: Private PlacementMarch 27, 2023
Details:
The updated interim results from the Phase 1 trial establish clinical proof of concept of HPN217 in heavily pretreated relapsed/refractory multiple myeloma and provide further clinical validation of our proprietary TriTAC T cell engager platform.
Lead Product(s):
HPN217
Therapeutic Area: Oncology Product Name: HPN217
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
AbbVie Inc
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableNovember 03, 2022
Details:
HPN328, a Tri-specific T cell Activating Construct (TriTAC®), is being evaluated as monotherapy in an ongoing open-label, multicenter two-part study to assess the safety, tolerability and pharmacokinetics in patients with advanced cancers associated with expression of DLL3.
Lead Product(s):
HPN328
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableMay 26, 2022
Details:
Under the supply agreement with Roche as it enables us to investigate the impact of HPN328 on solid tumors in combination with atezolizumab and provide further insight into the capabilities of our TriTAC technology platform.
Lead Product(s):
HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
F. Hoffmann-La Roche
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: CollaborationMay 02, 2022
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
